Ip S, Chung M, Raman G, Trikalinos TA, Lau J A summary of the Agency for Healthcare Research and Quality's evidence report on breastfeeding in developed countries. Breastfeed Med. 2009 Oct;4 Suppl 1:S17-30. doi: 10.1089/bfm.2009.0050. Review.
Jain BK Vitamin requirements of very low birth weight infants: a review. Indian J Matern Child Health. 1994 Apr-Jun;5(2):46-9.
Kalyoncu O, Aygün C, Cetinoglu E, Küçüködük S Neonatal morbidity and mortality of late-preterm babies. J Matern Fetal Neonatal Med. 2010 Jul;23(7):607-12. doi: 10.1080/14767050903229622.
Lapillonne A, O'Connor DL, Wang D, Rigo J Nutritional recommendations for the late-preterm infant and the preterm infant after hospital discharge. J Pediatr. 2013 Mar;162(3 Suppl):S90-100. doi: 10.1016/j.jpeds.2012.11.058.
Lucas A, Morley R, Cole TJ, Gore SM A randomised multicentre study of human milk versus formula and later development in preterm infants. Arch Dis Child Fetal Neonatal Ed. 1994 Mar;70(2):F141-6.
Lucas A, Morley R, Cole TJ Randomised trial of early diet in preterm babies and later intelligence quotient. BMJ. 1998 Nov 28;317(7171):1481-7.
Meier P, Patel AL, Wright K, Engstrom JL Management of breastfeeding during and after the maternity hospitalization for late preterm infants. Clin Perinatol. 2013 Dec;40(4):689-705. doi: 10.1016/j.clp.2013.07.014. Epub 2013 Sep 21. Review.
Raju TN, Higgins RD, Stark AR, Leveno KJ Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics. 2006 Sep;118(3):1207-14.
Schanler RJ, Lau C, Hurst NM, Smith EO Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. Pediatrics. 2005 Aug;116(2):400-6.
Schanler RJ, Shulman RJ, Lau C Feeding strategies for premature infants: beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics. 1999 Jun;103(6 Pt 1):1150-7.
Torrazza RM, Neu J The altered gut microbiome and necrotizing enterocolitis. Clin Perinatol. 2013 Mar;40(1):93-108. doi: 10.1016/j.clp.2012.12.009. Review.
Valentine G, Chu DM, Stewart CJ, Aagaard KM Relationships Between Perinatal Interventions, Maternal-Infant Microbiomes, and Neonatal Outcomes. Clin Perinatol. 2018 Jun;45(2):339-355. doi: 10.1016/j.clp.2018.01.008. Epub 2018 Feb 23. Review.
Walker M Breastfeeding the late preterm infant. J Obstet Gynecol Neonatal Nurs. 2008 Nov-Dec;37(6):692-701. doi: 10.1111/j.1552-6909.2008.00293.x. Review.
Young L, Morgan J, McCormick FM, McGuire W Nutrient-enriched formula versus standard term formula for preterm infants following hospital discharge. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD004696. doi: 10.1002/14651858.CD004696.pub4. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 13;12 :CD004696.
Use of Human Milk-Based Diet in the Late Preterm and Term Infant in the Neonatal Intensive Care Unit: A Pilot Randomized Controlled Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.